Gene-Targeted drug aims to prevent second heart attacks
Disease control
Recruiting now
This phase 3 trial tests whether the drug dalcetrapib can reduce the risk of major heart problems like heart attacks in people who have a specific genetic makeup (AA genotype) and have recently had a heart-related event. About 2,000 participants will receive either dalcetrapib or…
Phase: PHASE3 • Sponsor: DalCor Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC